Myriad Genetics, Inc.

565 articles with Myriad Genetics, Inc.

• IPM Launches Innovative Program for Rheumatoid Arthritis

  11/30/2020

  Integrated Prescription Management, a leading pharmacy benefits management company, has signed a contract with Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, to launch a ground-breaking personalized multibiomarker program for people with rheumatoid arthritis.

• Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China

  11/16/2020

  Myriad Genetics, Inc., a global leader in molecular diagnostics and precision medicine, announced the expansion of Myriad myChoice® tumor testing in several European markets and China.

• Burning Rock Announces In-Licensing of Myriad myChoice® Tumor Testing in China

  11/16/2020

  Burning Rock Biotech Limited announced that it entered into a development and commercialization agreement with Myriad Genetics, Inc. which will bring myChoice® tumor testing for homologous recombination deficiency, or HRD, to China.

• Myriad Genetics to Announce Quarterly Financial Results on November 9, 2020

  11/4/2020

  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its quarterly earnings conference call for the period ending September 30, 2020 with investors and analysts at 5 p.m. EST on Monday, November 9, 2020.

• Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests

  10/15/2020

  Myriad Genetics, Inc., a global leader in molecular diagnostics and precision medicine, announced that the company has filed its fiscal year 2020 proxy statement and made significant changes to its board structure, executive compensation and corporate governance policies to better serve key company stakeholders.

• Myriad Genetics Expands Board of Directors with New MemberRashmi Kumar Elected to Myriad’s Board of Directors

  9/10/2020

  Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the election of Rashmi Kumar, age 51, to its Board of Directors, effective immediately, expanding the Board to 12 members.  Additionally, Ms. Kumar was appointed to the Audit and Finance Committee of Myriad’s Board. Ms. Kumar is Senior Vice President and Global Chief Information Officer of Hewlett

• American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer

  8/21/2020

  Myriad Genetics, Inc., a global leader in molecular diagnostics and precision medicine, announced that the American Society of Clinical Oncology has exclusively included Myriad’s myChoice® CDx test in its new recommendations on the use of PARP inhibitors for the treatment and management of certain patients with advanced ovarian cancer.

• Myriad Genetics Announces Inducement Awards

  8/14/2020

  Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced that in connection with the previously announced appointment of Paul J. Diaz as President and Chief Executive Officer of the Company, effective yesterday, August 13, 2020, the Company’s Board of Directors authorized the grant to Mr. Diaz of (i) a restricted stock unit award for 298,954 shares of the C

• Myriad Genetics Reports Fiscal Fourth-Quarter 2020 Financial Results

  8/13/2020

  Test Volumes Improved Meaningfully By the End of the Fourth Quarter Following Substantial Declines in March and April Due to the Initiation of Social Distancing Policies Total Fourth-Quarter Revenues of $93.2 Million Fourth-Quarter Diluted EPS of ($0.74) and Adjusted EPS of ($0.31) SALT LAKE CITY, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced financia

• Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors

  8/13/2020

  Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the appointment of Paul J. Diaz as President and Chief Executive Officer, effective August 13, 2020.

• New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions

  8/10/2020

  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today a new study published in the peer-reviewed journal Genetics in Medicine demonstrates the limitations of ethnicity-based medical guidelines in identifying couples at risk for a pregnancy affected by serious genetic conditions.

• Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020

  8/6/2020

  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal fourth-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m. EDT on Thursday, August 13, 2020.  During the call, R. Bryan Riggsbee, interim president and CEO and chief financial officer, and Scott Gleason, senior vice president of Investor Relations and Corporate Strategy, will

• Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer

  7/31/2020

  Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that Medicare has expanded coverage for BRACAnalysis® CDx for men with prostate cancer who are eligible or may become eligible for treatment Lynparza®.

• Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS Test

  7/29/2020

  Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that the company has launched its proprietary AMPLIFY™ technology, which further increases the performance of its Prequel™ noninvasive prenatal screening test.

• Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra®

  7/28/2020

  Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that the company has launched a new enhancement that is now available on its Vectra® test report.

• Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D.

  7/22/2020

  Daniel M. Skovronsky, M.D., Ph.D. Elected to Myriad’s Board of Directors. Walter (Wally) Gilbert, Ph.D., announces upcoming retirement from the Board of Directors

• Myriad Announces New Studies Validating the Ability of Myriad’s riskScore® Test to Modify Breast Cancer Risk Prediction

  7/7/2020

  Publications Demonstrate the Ability of the PRS Component of riskScore® to Accurately Stratify Breast Cancer Risk in Women Both With and Without Pathogenic Mutations

• Myriad Announces Partnership with OptraHEALTH® to Deliver “Gene™” a New AI Based Information Tool for Hereditary Cancer Patients

  7/6/2020

  Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced a new collaboration with OptraHEALTH® to implement a cognitive ChatBOT named Gene™ to provide genetic and financial assistance information to prospective patients.

• Myriad Launches New GeneSight® Psychotropic Patient Collection KitClinicians Seeing Patients Remotely Can Now Offer Home DNA Sample Collection

  7/1/2020

  Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced the launch of a new patient home collection kit for the GeneSight® Psychotropic test.

• New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment

  6/25/2020

  Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that a new study published in Future Medicine demonstrates the ability of myPath® Melanoma to accurately classify skin lesions ruled indeterminate by standard pathological review.